Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Topicus.com Coöperatief U.A. and Topicus.com Inc. declare a special dividend
-
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
-
W&T Offshore Announces Fourth Quarter and Full Year 2023 Results Including Year-End 2023 Proved Reserves, Provides Guidance for 2024, and Declares Dividend for First Quarter of 2024
-
Bird Construction Inc. Announces 2023 Fourth Quarter and Annual Financial Results
-
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-90
-
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
-
Wall Street Journal highlights real-world implications of technical debt
-
LGI Homes, Inc. Reports February 2024 Home Closings
-
Prelude Announces Acceptance of Multiple Preclinical Abstracts at the 2024 AACR Annual Meeting
-
Pyxis Oncology to Present New PYX-201, PYX-106 and PYX-102 Preclinical Data at AACR Annual Meeting
-
Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024
-
Kronos Bio To Present Three Posters at AACR 2024 Annual Meeting
-
IO Biotech Announces 2023 Fourth-Quarter and Year-End Results
-
Intuitive Machines Announces Date for Fourth Quarter and Full-Year 2023 Financial Results Conference Call
-
ROSEN, LEADING INVESTOR COUNSEL, Encourages Thoughtworks Holding, Inc. Investors to Inquire About Securities Class Action Investigation – TWKS
-
Notable Labs to Present Two Posters at AACR 2024 on PPMP Platform
-
Precede Biosciences to Present Scientific Data For Its Comprehensive Epigenomic Liquid Biopsy Platform at AACR 2024
-
Mural Oncology Announces Upcoming Presentations at 2024 American Association for Cancer Research (AACR) Annual Meeting
-
DMG Blockchain Solutions Announces February Mining Results
-
Sisecam Reported a Net Sales of TRY 152 Billion in 2023
-
Quanta Therapeutics Announces Late-Breaking Presentation of QTX3544, a G12V-preferring multi-KRAS inhibitor, at AACR Annual Meeting
-
Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
-
Inspirato Announces 2023 Revenue and Adjusted EBITDA within Previously Guided Ranges, Provides 2024 Guidance
-
Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9,
-
Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting
-
Fitell Corporation Announces First Half-Year Financial Results
-
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
-
Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting
-
IN8bio to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024
-
Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
-
Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression
-
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
-
C4 Therapeutics to Present New Preclinical Data on Highly Selective Orally Bioavailable BiDAC™ Degraders at the American Association for Cancer Research Annual Meeting 2024
-
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
-
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
-
Lyell Immunopharma Announces the Acceptance of Three Abstracts for Presentation at 2024 AACR Annual Meeting
-
23andMe Announces Three Presentations from Clinical-Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024
-
iSpecimen to Report Full Year 2023 Financial Results on March 13, 2024
-
Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
-
Tarsus to Participate at Upcoming Investor Conferences
-
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
-
Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024
-
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
-
Mestag Therapeutics’ M300 Program, Designed to Conditionally Induce Tertiary Lymphoid Structures in Tumors, Selected for Late-Breaking Poster Presentation at AACR Annual Meeting
-
Acrivon Therapeutics to Present Data at AACR Annual Meeting Demonstrating Power of Acrivon Predictive Precision Proteomics (AP3) Platform and its Internally-Discovered, Potent WEE1/PKMYT1 Development
-
Updated Results from Single-Agent Phase 1 Clinical Trial of Peptide Drug Conjugate, AVA6000 to be Presented in a Poster at the American Association of Cancer Research (AACR) Annual Meeting on April 9,
-
Immunocore presented two posters at CROI 2024
-
Viper Energy Launches Secondary Common Stock Offering By Diamondback Energy, Inc.
-
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
-
Grupo Aeroportuario del Pacifico Reports in February 2024 A Passenger Traffic Increase of 1.7% Compared to 2023
